Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer

BACKGROUND: Currently, no effective treatments exist for non-small cell lung cancer (NSCLC) after failure of gefitinib therapy. Pre-clinical studies have demonstrated that gefitinib-resistant NSCLC cells are more sensitive to irinotecan than parental cells, and that combined administration of irinot...

Descripción completa

Detalles Bibliográficos
Autores principales: Horiike, A, Kudo, K, Miyauchi, E, Ohyanagi, F, Kasahara, K, Horai, T, Nishio, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208500/
https://www.ncbi.nlm.nih.gov/pubmed/21915126
http://dx.doi.org/10.1038/bjc.2011.375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208500/
https://www.ncbi.nlm.nih.gov/pubmed/21915126
http://dx.doi.org/10.1038/bjc.2011.375

Ejemplares similares